An observational study in Cardiac Arrest (CA), Cerebrospinal Fluid and Multiomics, sponsored by Chungnam National University Hospital. Recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.
Sponsored by Chungnam National University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Heart Arrest with a site in Korea, Republic of — 8 open to participants now, 10 under way, none of them phase 3. Heart Arrest · Korea, Republic of.
Among the 44 studies in Heart Arrest with a site in Korea, Republic of, this one is the 16th largest by planned enrollment of the 22 observational ones that give a count, is one of 3 that started in 2025, is one of 22 observational ones, and was the 42nd registered.
927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.
Browse Heart Arrest studies →8 of the 44 studies in Heart Arrest with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Seoul National University Hospital · Sites in Korea, Republic of
Ages 18–50 · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 18+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 20–80
Korea University Ansan Hospital · Sites in Korea, Republic of
Ages 19–80 · Healthy volunteers
Children's Hospital of Philadelphia · Sites in Korea, Republic of, United States, Australia and 12 more countries
Ages 0–18
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 200 across 376 observational studies indexed under Heart Arrest.
Median enrollment 63 across the 22 interventional studies, 195 across the 22 observational. Of the 23 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 44 have an industry lead sponsor. The 10 most frequent:
Chungnam National University Hospital is the lead sponsor of 22 studies on the registry; 13 are open to participants now.
Chungnam National University Hospital has 3 studies filed under Heart Arrest — fewer than ten, so there is no comparison to draw.
4 of the studies in Heart Arrest with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07090577Chungnam National University HospitalMultiomics Profiling of CSF in Cardiac Arrest Survivors | 2026-12-31 |
| NCT07363772Seoul National University HospitalEvaluation of Mixed Reality Cardiopulmonary Resuscitation Training | 2026-12-31 |
| NCT05830422Chungnam National University HospitalPrediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes | 2027-03-31 |
| NCT07481396Chungnam National University HospitalMolecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies in Heart Arrest with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.
The main question this study aims to answer is:
Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?
To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.
The study population for this research consists of a highly specific and clinically critical group of patients: Adults who have experienced out-of-hospital or in-hospital cardiac arrest and successfully regained spontaneous circulation (ROSC), but remain at high risk for secondary brain injury.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The favorable neurological outcome group is classified as patients with a CPC score of 1 or 2 upon long-term follow-up (at discharge, 3 months after post-resuscitation)
The favorable neurological outcome group is classified as patients with a CPC score of 3 to 5 upon long-term follow-up (at discharge, 3 months after post-resuscitation)
Neurological outcome
Neurological outcome assessed using the Cerebral Performance Category (CPC) scale (range 1-5; lower scores indicate better neurological function).
Time frame: at discharge (assessed up to 3 days), 3 months after return of spontaneous circulation (ROSC)
Plan to share: Undecided
Started Dec 2025 (actual). Primary completion is estimated for Nov 2027, 23 months after the start.
Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 23 months is below that.
Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chungnam National University Hospital